Assembly Biosciences Inc. (V7B)
XFRA 
Summary
V7B Chart
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts
Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients, with a 94% reduction in HSV-2 shedding and genital lesion rates. Upcoming catalysts include monthly dosing data for ABI-5366 and phase 1b data for ABI-1179, both expected in fall 2025, plus potential Gilead opt-in milestones. ASMB addresses a major unmet need, as no new HSV-2 therapies have been approved in 25+ years and the market could reach $4B by 2030.
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago.
Assembly Biosciences Inc. (V7B) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Assembly Biosciences Inc. ever had a stock split?
Assembly Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jason A. Okazaki CEO | XFRA Exchange | US0453962070 ISIN |
| US Country | 73 Employees | - Last Dividend | 12 Feb 2024 Last Split | 17 Dec 2010 IPO Date |
Overview
Assembly Biosciences, Inc., established in 2005 and based in South San Francisco, California, is a biopharmaceutical entity focused on the discovery and advancement of therapeutic solutions aimed at combating hepatitis B virus (HBV) infection. Initially known as Ventrus Biosciences, Inc., the company underwent a rebranding to Assembly Biosciences, Inc. in June 2014. Engaged in cutting-edge research, Assembly Biosciences is pioneering the development of next-generation HBV core inhibitors and exploring innovative small molecule therapies not only for HBV but also for hepatitis delta virus (HDV) and herpesvirus. The company's dedication to tackling viral diseases extends through multiple partnerships and collaborations, including agreements with BeiGene, Ltd., Arbutus Biopharma Corporation, Antios Therapeutics, Inc., Indiana University Research and Technology Corporation, and Gilead Sciences, Inc. These strategic alliances are formed to amplify its research capabilities and bolster the development and commercialization of its groundbreaking therapeutic candidates.
Products and Services
- ABI-4334 - A next-generation HBV core inhibitor currently undergoing Phase 1a studies. This candidate represents the company's commitment to developing potent antivirals targeted at HBV infection.
- ABI-H3733 - Another HBV core inhibitor from Assembly's pipeline, ABI-H3733, is in Phase 1b clinical study, indicating a further extension of the company's endeavors in combating HBV through innovative therapies.
- Orally Bioavailable HBV/HDV Entry Inhibitor and Liver-Focused Interferon-a Receptor Agonist - These novel small molecule approaches aim at disrupting the HBV and HDV lifecycle, offering new hope for patients battling these infections.
- Herpesvirus Programs:
- ABI-5366 HSV-2 - A long-acting helicase inhibitor focused on managing herpes simplex virus type 2 (HSV-2). This program showcases Assembly Biosciences' efforts to extend its antiviral research beyond hepatitis to address other critical viral infections.
- Pan-Herpes Non-Nucleoside Polymerase Inhibitors - Aimed at treating transplant-associated infections, this development underscores the company's commitment to broadening the scope of its antiviral therapies.
- Collaboration Agreements - These include:
- A partnership with BeiGene, Ltd. to advance the commercialization of novel core inhibitor product candidates for chronic HBV infection in China and its territories.
- A clinical trial collaboration with Arbutus Biopharma Corporation for conducting randomized, multi-center, and open-label clinical studies.
- Agreement with Antios Therapeutics, Inc. focusing on triple combination therapy, further exemplifying Assembly Biosciences' dedication to exploring synergistic treatment modalities.
- A license agreement with Indiana University Research and Technology Corporation and a partnership with Gilead Sciences, Inc. to foster the development of next-generation therapeutics for serious viral diseases.
